What is Lyell Immunopharma, Inc. Common Stock's Market Cap?

Lyell Immunopharma, Inc. Common Stock's Market Cap is $331.6M, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's Enterprise Value?

Lyell Immunopharma, Inc. Common Stock's Enterprise Value is $127.5M, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's Price / Sales?

Lyell Immunopharma, Inc. Common Stock's Price / Sales is 12279.8×, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's EV / Revenue?

Lyell Immunopharma, Inc. Common Stock's EV / Revenue is 4720.5×, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's EV / EBITDA?

Lyell Immunopharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's Revenue (TTM)?

Lyell Immunopharma, Inc. Common Stock's Revenue (TTM) is $27.0K, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's Net Income (TTM)?

Lyell Immunopharma, Inc. Common Stock's Net Income (TTM) is -$248.5M, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's EBITDA?

Lyell Immunopharma, Inc. Common Stock's EBITDA is -$247.0M, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's Diluted EPS (TTM)?

Lyell Immunopharma, Inc. Common Stock's Diluted EPS (TTM) is -10.14, based on as-reported figures from SEC (XBRL) filings.

What is Lyell Immunopharma, Inc. Common Stock's EBITDA Margin?

Lyell Immunopharma, Inc. Common Stock's EBITDA Margin is -914733.3%, based on as-reported figures from SEC (XBRL) filings.

Lyell Immunopharma, Inc. Common Stock (LYEL) Financial Statements

Lyell Immunopharma, Inc. Common Stock

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG00RNXFN23

XNAS · usd

13.53▼ 0.84 (-5.85%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close14.37

Day's Range13.37 – 14.13

52-Week Range11.47 – 45.00

Volume82.3K

Avg Volume143.3K

Share Statistics

Shares Outstanding

Employees161

ExchangeXNAS

Listed2021-06-17

Share count as of August 3, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Lyell Immunopharma, Inc. Common Stock (LYEL)

What is Lyell Immunopharma, Inc. Common Stock's Market Cap?: Lyell Immunopharma, Inc. Common Stock's Market Cap is $331.6M, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's Enterprise Value?: Lyell Immunopharma, Inc. Common Stock's Enterprise Value is $127.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's Price / Sales?: Lyell Immunopharma, Inc. Common Stock's Price / Sales is 12279.8×, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's EV / Revenue?: Lyell Immunopharma, Inc. Common Stock's EV / Revenue is 4720.5×, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's EV / EBITDA?: Lyell Immunopharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's Revenue (TTM)?: Lyell Immunopharma, Inc. Common Stock's Revenue (TTM) is $27.0K, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's Net Income (TTM)?: Lyell Immunopharma, Inc. Common Stock's Net Income (TTM) is -$248.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's EBITDA?: Lyell Immunopharma, Inc. Common Stock's EBITDA is -$247.0M, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's Diluted EPS (TTM)?: Lyell Immunopharma, Inc. Common Stock's Diluted EPS (TTM) is -10.14, based on as-reported figures from SEC (XBRL) filings.
What is Lyell Immunopharma, Inc. Common Stock's EBITDA Margin?: Lyell Immunopharma, Inc. Common Stock's EBITDA Margin is -914733.3%, based on as-reported figures from SEC (XBRL) filings.